| Serial Number | 88329711 |
| Word Mark | AMGEN BIOSIMILARS |
| Filing Date | Thursday, March 7, 2019 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, February 13, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, November 12, 2019 |
| Description of Mark | The mark consists of the stylized words "AMGEN BIOSIMILARS" positioned to the right of an interweaving double ribbon design. |
| Goods and Services | House mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Disclaimer with Predetermined Text | "BIOSIMILARS" |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, March 25, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Amgen Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Thousand Oaks, CA 913201799 |
| Party Name | Amgen Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Thousand Oaks, CA 913201799 |
| Event Date | Event Description |
| Monday, February 13, 2023 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, February 13, 2023 | ABANDONMENT - NO USE STATEMENT FILED |
| Thursday, June 16, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, June 15, 2022 | SOU EXTENSION 5 GRANTED |
| Tuesday, June 7, 2022 | SOU EXTENSION 5 FILED |
| Wednesday, June 15, 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Tuesday, June 7, 2022 | SOU TEAS EXTENSION RECEIVED |
| Thursday, December 2, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, November 30, 2021 | SOU EXTENSION 4 GRANTED |
| Tuesday, November 30, 2021 | SOU EXTENSION 4 FILED |
| Tuesday, November 30, 2021 | SOU TEAS EXTENSION RECEIVED |
| Thursday, May 6, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, May 6, 2021 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
| Thursday, May 6, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Thursday, May 6, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Thursday, May 6, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, May 4, 2021 | SOU EXTENSION 3 GRANTED |
| Tuesday, May 4, 2021 | SOU EXTENSION 3 FILED |
| Tuesday, May 4, 2021 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, December 22, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, December 18, 2020 | SOU EXTENSION 2 GRANTED |
| Friday, December 18, 2020 | SOU EXTENSION 2 FILED |
| Friday, December 18, 2020 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, July 1, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, June 29, 2020 | SOU EXTENSION 1 GRANTED |
| Monday, June 29, 2020 | SOU EXTENSION 1 FILED |
| Monday, June 29, 2020 | SOU TEAS EXTENSION RECEIVED |
| Monday, March 2, 2020 | ASSIGNED TO EXAMINER |
| Tuesday, January 7, 2020 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, November 12, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 12, 2019 | PUBLISHED FOR OPPOSITION |
| Wednesday, October 23, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, October 9, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, October 4, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, October 4, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, September 23, 2019 | ASSIGNED TO LIE |
| Thursday, September 12, 2019 | ASSIGNED TO LIE |
| Friday, September 6, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, March 30, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, March 30, 2019 | NON-FINAL ACTION E-MAILED |
| Saturday, March 30, 2019 | NON-FINAL ACTION WRITTEN |
| Tuesday, March 26, 2019 | ASSIGNED TO EXAMINER |
| Tuesday, March 26, 2019 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Monday, March 25, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, March 11, 2019 | NEW APPLICATION ENTERED |